Abstract
Background
CD133 is a membrane glycoprotein containing five transmembrane loops. Previous reports suggest that a CD133-positive subpopulation of multipotent cells with extensive proliferative and self-renewal characteristics has biological features of a cancer stem cell. In addition, the presence of CD133-positive cells was associated with a significantly poorer prognosis for some solid tumors, compared to those with CD133-negative cells. However, the clinicopathological significance of CD133 in non-small cell lung cancer (NSCLC) remains controversial.
Methods
We conducted immunohistochemical assessment of 161 NSCLCs surgically resected at Hokkaido University Hospital between 1982 and 1994 to evaluate correlations between CD133 expression and various clinicopathological features.
Results
CD133 expression was significantly correlated with pathological stages (pStages) II, III, and IV for the various NSCLC types analyzed and was an independent factor for unfavorable prognosis in this population (hazard ratio = 3.157, P = 0.015).
Conclusion
CD133 expression was correlated with pStage and was predictive of unfavorable prognosis in patients with pStages II, III, and IV NSCLC. These results suggest the possibility of using CD133 as a novel prognostic marker in these patients.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249
Miraglia S, Godfrey W, Yin AH et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021
Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature (Lond) 445:111–115
Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature (Lond) 432:396–401
Horst D, Kriegl L, Engel J et al (2008) CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99:1285–1289
Zeppernick F, Ahmadi R, Campos B et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123–129
Zhao P, Li Y, Lu Y (2010) Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 10:218
Song W, Li H, Tao K et al (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62:1212–1218
Salnikov AV, Kusumawidjaja G, Rausch V et al (2009) Cancer stem cell marker expression in hepatocellular carcinoma and liver metastasis is not sufficient as single prognostic parameter. Cancer Lett 275:185–193
Donnenberg VS, Landreneau RJ, Donnenberg AD (2007) Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents. J Control Release 122:385–391
Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281–16286
Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4:32–42
Zhang HZ, Wei YP, Wang M et al (2007) Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27:696–699
Salnikov AV, Gladkich J, Moldenhauer G et al (2010) CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126:950–958
Li F, Zeng H, Ying K (2010) The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28:1458–1462
Beahrs O, Henson D, Hutter R et al (1992) AJCC manual for staging of cancer, lung. Lippincott, Philadelphia
Hermansen SK, Christensen KG, Jensen SS et al (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59:391–407
Sasaki A, Kamiyama T, Yokoo H et al (2010) Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 24:537–546
Sagrinati C, Netti GS, Mazzinghi B et al (2006) Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J Am Soc Nephrol 17:2443–2456
Hilbe W, Dirnhofer S, Oberwasserlechner F et al (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965–969
Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253–1261
Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature (Lond) 414:105–111
Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951
Suetsugu A, Nagaki M, Aoki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820–824
Eramo A, Lotti F, Sette G et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514
Horst D, Scheel SK, Liebmann S et al (2009) The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 219:427–434
Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768
Shmelkov SV, Butler JM, Hooper AT et al (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133− metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111–2120
Janikova M, Skarda J, Dziechciarkova M et al (2010) Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:321–326
Acknowledgments
We thank Namie Sawada (Department of Medical Oncology, Hokkaido University Graduate School of Medicine) for special support and experimental assistance.
Conflict of interest
All authors report that they have no financial conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mizugaki, H., Sakakibara-Konishi, J., Kikuchi, J. et al. CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 19, 254–259 (2014). https://doi.org/10.1007/s10147-013-0541-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-013-0541-x